The role of complement in autoimmune renal disease

Autoimmunity

Volumn 39, Issue 5, 2006, Pages 411-415

  Seelen, M A ^a   Daha, M R ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoantibodies; Autoimmune diseases; Complement activation; Subepithelial immune complex

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; DOUBLE STRANDED DNA ANTIBODY; FAS ANTIGEN; FC RECEPTOR; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; NEPHRITIC FACTOR; RAG2 PROTEIN; RECOMBINANT COMPLEMENT COMPONENT C3B RECEPTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEFICIENCY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DRUG EFFICACY; GENETIC PREDISPOSITION; GLOMERULUS BASEMENT MEMBRANE; GOODPASTURE SYNDROME; HEYMANN NEPHRITIS; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS;

ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33747629735     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600739688     Document Type: Article

References (34)

1. Walport, MJ. (2001) Complement. Second of two parts N Engl J Med, 344, pp. 1140-1144.
2. Walport, MJ. (2001) Complement. First of two parts N Engl J Med, 344, pp. 1058-1066.
3. Turner, N and Mason, PJ and Brown, R and (1992) Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen J Clin Invest, 89, pp. 592-601.
4. Sheerin, NS and Springall, T and Carroll, MC and Hartley, B and Sacks, SH. (1997) Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice Clin Exp Immunol, 110, pp. 403-409.
5. Cunningham, PN and Quigg, RJ. (2005) Contrasting roles of complement activation and its regulation in membranous nephropathy J Am Soc Nephrol, 16, pp. 1214-1222.
6. Appel, GB and Cook, HT and Hageman, G and (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): An update J Am Soc Nephrol, 16, pp. 1392-1403.
7. Daha, MR and Hazevoet, HM and Vanes, LA and Cats, A. (1980) Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus Immunology, 40, pp. 417-424.
8. Mok, CC and Lau, CS. (2003) Pathogenesis of systemic lupus erythematosus J Clin Pathol, 56, pp. 481-490.
9. Walport, MJ and Davies, KA and Botto, M. (1998) C1q and systemic lupus erythematosus Immunobiology, 199, pp. 265-285.
10. Siegert, C and Daha, M and Westedt, ML and van der Voort, E and Breedveld, F. (1991) IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus J Rheumatol, 18, pp. 230-234.
11. Smeenk, R and Brinkman, K and van den Brink, H and (1990) Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease Clin Rheumatol, 9, pp. 100-110.
12. Arbuckle, MR and McClain, MT and Rubertone, MV and (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus N Engl J Med, 349, pp. 1526-1533.
13. Gunnarsson, I and Sundelin, B and Heimburger, M and (2002) Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria J Rheumatol, 29, pp. 693-699.
14. Mannik, M and Wener, MH. (1997) Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis Arthritis Rheum, 40, pp. 1504-1511.
15. Trouw, LA and Seelen, MA and Visseren, R and (2004) Anti-C1q autoantibodies in murine lupus nephritis Clin Exp Immunol, 135, pp. 41-48.
16. Winfield, JB and Faiferman, I and Koffler, D. (1977) Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis J Clin Invest, 59, pp. 90-96.
17. Trouw, LA and Seelen, MA and Duijs, JM and Benediktsson, H and van Kooten, C and Daha, MR. (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies Clin Exp Immunol, 132, pp. 32-39.
18. Trouw, LA and Groeneveld, TW and Seelen, MA and (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes J Clin Invest, 114, pp. 679-688.
19. Trouw, LA and Daha, MR. (2005) Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis Expert Opin Biol Ther, 5, pp. 243-251.
20. Manderson, AP and Botto, M and Walport, MJ. (2004) The role of complement in the development of systemic lupus erythematosus Annu Rev Immunol, 22, pp. 431-456.
21. Botto, M and Walport, MJ. (2002) C1q, autoimmunity and apoptosis Immunobiology, 205, pp. 395-406.
22. Casciola-Rosen, LA and Anhalt, G and Rosen, A. (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes J Exp Med, 179, pp. 1317-1330.
23. Nauta, AJ and Daha, MR and van Kooten, C and Roos, A. (2003) Recognition and clearance of apoptotic cells: A role for complement and pentraxins Trends Immunol, 24, pp. 148-154.
24. Ogden, CA and deCathelineau, A and Hoffmann, PR and (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells J Exp Med, 194, pp. 781-795.
25. Botto, M and Dell'Agnola, C and Bygrave, AE and (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies Nat Genet, 19, pp. 56-59.
26. Mold, C and Baca, R and Du Clos, TW. (2002) Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors J Autoimmun, 19, pp. 147-154.
27. Nauta, AJ and Raaschou-Jensen, N and Roos, A and (2003) Mannose-binding lectin engagement with late apoptotic and necrotic cells Eur J Immunol, 33, pp. 2853-2863.
28. Shaw, PX and Horkko, S and Chang, MK and (2000) Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity J Clin Invest, 105, pp. 1731-1740.
29. Trouw, LA and Seelen, MA and Duijs, JM and (2005) Activation of the lectin pathway in murine lupus nephritis Mol Immunol, 42, pp. 731-740.
30. Asghar, SS and Pasch, MC. (2000) Therapeutic inhibition of the complement system, Y2K update Front Biosci, 5, pp. E63-E81.
31. Bao, L and Haas, M and Kraus, DM and (2003) Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice J Am Soc Nephrol, 14, pp. 670-679.
32. Couser, WG and Johnson, RJ and Young, BA and Yeh, CG and Toth, CA and Rudolph, AR. (1995) The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis J Am Soc Nephrol, 5, pp. 1888-1894.
33. Bao, L and Osawe, I and Puri, T and Lambris, JD and Haas, M and Quigg, RJ. (2005) C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist Eur J Immunol, 35, pp. 2496-2506.
34. Wang, Y and Hu, Q and Madri, JA and Rollins, SA and Chodera, A and Matis, LA. (1996) Amelioration of lupus-like autoimmune disease in NZB/ WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 Proc Natl Acad Sci U.S.A, 93, pp. 8563-8568.